Surprise as Astellas drops SGLT2 contender ipragliflozin at Phase II in US/Europe
This article was originally published in Scrip
Executive Summary
Astellas has decided to discontinue the US and European Phase II development of its sodium/glucose co-transporter 2 (SGLT2) inhibitor ipragliflozin (ASP1941; licensed from Kotobuki Pharmaceutical), citing purely commercial reasons.